Life Sciences Commons^™

Microrna-26a-5p As A Potential Predictive Factor For Determining The Effectiveness Of Trastuzumab Therapy In Her-2 Positive Breast Cancer Patients, Sadra Samavarchi Tehrani, Ehsan Zaboli, Farzin Sadeghi, Soraya Khafri, Ansar Karimian, Mahnoosh Rafie, Hadi Parsian

BioMedicine

Background: Breast cancer (BC) is known as the most prevalence type of cancer among women. Trastuzumab, as a cancer drug, has been used broadly in human epidermal growth factor receptor 2 (HER-2) positive BC patients. On the other hand, accumulating evidence has demonstrated that microRNAs involved in pathogenesis BC. Hence, we aimed to investigate the effect of trastuzumab on the expression levels of microRNA-26a in HER-2positiveBC patients.

Methods: This study was conducted on HER-2 positive BC patients and HER-2 Negative BC patients. Serum expression of microRNA-26a were detected by real-time PCR. Then, we assessed the correlation of microRNA-26a level with …

Breast Cancer Screening Implications Of Risk Modeling Among Female Relatives Of Atm And Chek2 Carriers, Anne E. Weidner, Mariel E. Liggin, Brenda I. Zuniga, Ann L. Tezak, Georgia L. Wiesner, Tuya Pal

Biology Student Research

Background

With the increasing use of multigene panel tests, pathogenic and likely pathogenic (P/LP) variants are identified more frequently in the moderate-penetrance breast cancer genes ATM and CHEK2. Lifetime breast cancer risk among women with P/LP variants in these genes generally exceeds 20%, meeting the threshold at which high-risk breast cancer screening through breast magnetic resonance imaging (MRI) is recommended.

Methods

Among a registry-based sample of 56 ATM and 69 CHEK2 carriers, the authors sought to determine the percentage of relatives in whom a P/LP variant would impact breast cancer surveillance. Lifetime breast cancer risks for unaffected, female first-degree …